Is GILD a buy? - Seeking Alpha

Quote & Headlines Market Currents StockTalk

Today 5d 1m 3m 1y 5y 10y

52wk high:

52wk low:

EPS:

PE:

Div Rate:

Yield:

Market Cap:

Volume:

7,003 people get GILD articles and Market Currents by email alert.

Get email alerts on GILD »

HEADLINES:

European Medicines Agency Validates Gilead’s Marketing Application for Sofosbuvir for the Treatment of Hepatitis C

Business Wire (Tue, 4:30PM)
Will Influenza A H7N9 Generate Opportunities For Pharma?
Jean-Christophe Larsimont • Tue, May 21 • 4 Comments
Cramer's Mad Money - The Kids Love Tesla (5/20/13)
SA Editor Miriam Metzinger • Tue, May 21 • 1 Comment
Gilead Sciences' Management Presents at the 2013 UBS Global Healthcare Conference (Transcript)
Mon, May 20
Gilead Sciences to Present at the 2013 UBS Global Healthcare Conference on Monday, May 20

Business Wire (Fri, 4:05PM)
Cramer's Lightning Round - I've Had It With Magnum Hunter (5/16/13)
SA Editor Miriam Metzinger • Fri, May 17 • 8 Comments
Gilead Announces Response Data from Phase 2 Study of Idelalisib for Previously Untreated Chronic Lymphocytic Leukemia

Business Wire (Wed, 6:30PM)
This Big Hedge Fund Is Bullish On Big Companies; Should You Be?
Insider Monkey • Mon, May 13 • 1 Comment
Nailing Big Winners In The Market
Bill Gunderson • Thu, May 9 • 3 Comments
Gilead's Hepatitis C Drug Sofosbuvir Offers Upside
Todd Campbell • Thu, May 9 • 4 Comments
Cramer's Mad Money - 10 Things To Watch In The Week Ahead (5/3/13)
SA Editor Miriam Metzinger • Sun, May 5 • 4 Comments
Cramer's Lightning Round - Akamai Goes From 'Nah' To 'Yeah' (5/2/13)
SA Editor Miriam Metzinger • Fri, May 3 • 1 Comment
Biotech Bulls Can Ignore The Warning Signs At Their Peril
EP Vantage • Thu, May 2 • 7 Comments
Gilead Sciences' CEO Discusses Q1 2013 Results - Earnings Call Transcript
Thu, May 2
Gilead Sciences Announces First Quarter 2013 Financial Results

Business Wire (May 2, 2013)
Gilead Reports Interim Data From Phase 2 LONESTAR Study

Business Wire (May 2, 2013)
United Therapeutics' Second PAH Stumble Emphasizes The Need For Pluristem's Therapy
Sharon di Stefano • Tue, Apr 30 • 6 Comments
Gilead Receives Complete Response Letters from U.S. Food and Drug Administration for Elvitegravir and Cobicistat

Business Wire (Apr 29, 2013)
S&P 500 Q1 Earnings Seem Positive: Is It Enough For More Gains?
Pendulum • Sun, Apr 28 • 11 Comments
Cramer's Mad Money - Why Analysts Were Wrong About Microsoft (4/25/13)
SA Editor Miriam Metzinger • Fri, Apr 26 • 11 Comments

To learn more about Seeking Alpha Pro, click here.

Gilead's Hepatitis C Drug Sofosbuvir Offers Upside
Todd Campbell • Thu, May 9 • 4 Comments
Whisper Number Impact: Earnings Preview For Gilead Sciences
WhisperNumber • Mon, Apr 22 • 4 Comments
Gilead Sciences - Keeping Up With The Times And Winning
Emerging Equities • Mon, Apr 15 • 1 Comment
Can Gilead Maintain Its Momentum?
Efsinvestment • Wed, Apr 10 • 11 Comments
Gilead Sciences: Stribild Recommended, Great Long-Term Hold
Nick Chiu • Tue, Mar 26 • 3 Comments
Gilead And Its Competitors In The Hepatitis C Race
Peter Geschek • Thu, Mar 21 • 7 Comments
Regulators Await Gilead's Hep C Candidate
EP Vantage • Thu, Feb 21 • 8 Comments
FISSION Study Should Support Regulatory Approval For Gilead's Hepatitis C Drug
Biomed Group • Thu, Feb 7 • 2 Comments
Whisper Number Impact: Earnings Preview For Gilead Sciences
WhisperNumber • Mon, Feb 4
Gilead Sciences: A Great Long-Term Buy And Heading Bullishly Into Earnings
Nick Chiu • Sat, Feb 2 • 6 Comments
Gilead Could Be A Smart Play On Hepatitis C Market Growth
Leopold Epstein • Mon, Jan 28 • 3 Comments
Gilead Sciences: How Long Can The Giddiness Last?
GMI Ratings • Thu, Dec 20, 2012 • 4 Comments
Gilead Sciences - Shares Continue To Have Appeal, Trading At All-Time Highs
The Value Investor • Mon, Dec 17, 2012
Gilead Sciences' Stock Dividend And What's Behind It
Peter Geschek • Fri, Dec 14, 2012 • 3 Comments
A Not-So-Bad Acquisition By Gilead
Henry Kawabe • Fri, Dec 14, 2012
How To Play Gilead Sciences At Its Sizzling Hot 52-Week High
Nick Chiu • Wed, Dec 12, 2012 • 2 Comments
Gilead Sciences Leads The Race In Developing A Hepatitis C Pill
Peter Geschek • Sat, Dec 8, 2012 • 2 Comments
Gilead Can Cure Your Portfolio With Sofobuvir
Stock Whisper • Thu, Dec 6, 2012
Gilead Sciences Pipeline Value
William Meyers • Tue, Dec 4, 2012
Is Gilead Sciences Still A Good Buy?
C.R. Jackson • Wed, Nov 28, 2012 • 1 Comment

Will Influenza A H7N9 Generate Opportunities For Pharma?
Jean-Christophe Larsimont • Tue, May 21 • 4 Comments
Cramer's Mad Money - The Kids Love Tesla (5/20/13)
SA Editor Miriam Metzinger • Tue, May 21 • 1 Comment
Cramer's Lightning Round - I've Had It With Magnum Hunter (5/16/13)
SA Editor Miriam Metzinger • Fri, May 17 • 8 Comments
This Big Hedge Fund Is Bullish On Big Companies; Should You Be?
Insider Monkey • Mon, May 13 • 1 Comment
Nailing Big Winners In The Market
Bill Gunderson • Thu, May 9 • 3 Comments
Cramer's Mad Money - 10 Things To Watch In The Week Ahead (5/3/13)
SA Editor Miriam Metzinger • Sun, May 5 • 4 Comments
Cramer's Lightning Round - Akamai Goes From 'Nah' To 'Yeah' (5/2/13)
SA Editor Miriam Metzinger • Fri, May 3 • 1 Comment
Biotech Bulls Can Ignore The Warning Signs At Their Peril
EP Vantage • Thu, May 2 • 7 Comments
United Therapeutics' Second PAH Stumble Emphasizes The Need For Pluristem's Therapy
Sharon di Stefano • Tue, Apr 30 • 6 Comments
S&P 500 Q1 Earnings Seem Positive: Is It Enough For More Gains?
Pendulum • Sun, Apr 28 • 11 Comments
Cramer's Mad Money - Why Analysts Were Wrong About Microsoft (4/25/13)
SA Editor Miriam Metzinger • Fri, Apr 26 • 11 Comments
Cramer's Mad Money - National Lemming Day (4/24/13)
SA Editor Miriam Metzinger • Thu, Apr 25
Investors May Want To Fade Healthcare In May
Todd Campbell • Wed, Apr 24 • 5 Comments
Weekly Options Active On Microsoft
Interactive Brokers • Mon, Apr 22
Biotech Stocks Get A Turbo Boost From Vertex
Rod Raynovich • Sat, Apr 20 • 3 Comments
These 4 'High-Potential' Biotech Stocks Could Outperform In 2013
Trade In Mexico • Thu, Apr 18 • 14 Comments
3 Microcap Biopharma Plays For The H7N9 Influenza Outbreak
Healthcare Specialist • Tue, Apr 16 • 18 Comments
Tuesday Options Brief: SFD, ELLI & GILD
Interactive Brokers • Tue, Apr 16 • 1 Comment
Achillion: Moving Beyond Sofosbuvir's Shadow
PropThink • Tue, Apr 16 • 1 Comment
S&P 500's P/E Rises To 16.4x As Q1 Results Start Coming In
Pendulum • Sun, Apr 14 • 4 Comments

Gilead Sciences' Management Presents at the 2013 UBS Global Healthcare Conference (Transcript)
Mon, May 20
Gilead Sciences' CEO Discusses Q1 2013 Results - Earnings Call Transcript
Thu, May 2
Gilead Sciences' CEO Discusses Q4 2012 Results - Earnings Call Transcript
Mon, Feb 4
Gilead Sciences Management Discusses Q3 2012 Results - Earnings Call Transcript
Tue, Oct 23, 2012
Gilead Sciences Management Discusses Q2 2012 Results - Earnings Call Transcript
Fri, Jul 27, 2012
Gilead Sciences Management Discusses Q1 2012 Results - Earnings Call Transcript
Thu, Apr 26, 2012
Gilead Sciences Inc. - Special Call
Wed, Mar 7, 2012
Gilead Sciences' CEO Discusses Q4 2011 Results - Earnings Call Transcript
Fri, Feb 3, 2012
Gilead Sciences' CEO Presents at The 30th Annual JPMorgan Chase Healthcare Conference (Transcript)
Mon, Jan 9, 2012
Gilead Sciences' CEO Discusses Q3 2011 Results - Earnings Call Transcript
Fri, Oct 28, 2011
Gilead Sciences' CEO Discusses Q2 2011 Results - Earnings Call Transcript
Tue, Jul 26, 2011
Gilead Sciences' CEO Discusses Q1 2011 Results - Earnings Call Transcript
Thu, Apr 21, 2011
Gilead Sciences' CEO Discusses Q4 2010 Results - Earnings Call Transcript
Wed, Jan 26, 2011
Gilead Sciences Inc. CEO Discusses Q3 2010 Earnings - Call Transcript
Tue, Oct 19, 2010
Gilead Sciences Inc. Q1 2010 Earnings Call Transcript
Wed, Apr 21, 2010 • 2 Comments
Gilead Sciences, Inc. Q4 2009 Earnings Call Transcript
Wed, Jan 27, 2010
Gilead Sciences, Inc. Q3 2009 Earnings Call Transcript
Wed, Oct 21, 2009
Gilead Sciences, Inc. Q2 2009 Earnings Call Transcript
Wed, Jul 22, 2009
Gilead Sciences Inc., Q1 2009 Earnings Call Transcript
Tue, Apr 21, 2009
Gilead Sciences Inc. Q4 2008 Earnings Call Transcript
Tue, Jan 27, 2009

European Medicines Agency Validates Gilead’s Marketing Application for Sofosbuvir for the Treatment of Hepatitis C

Business Wire (Tue, 4:30PM)
Cramer's Watch List Ahead of Big Cancer Conference

at CNBC.com (Mon, 6:26PM)
Gilead Sciences to Present at the 2013 UBS Global Healthcare Conference on Monday, May 20

Business Wire (Fri, 4:05PM)
Lightning Round: Starbucks, Gilead & More

at CNBC.com (Thu, 6:42PM)
Gilead Announces Response Data from Phase 2 Study of Idelalisib for Previously Untreated Chronic Lymphocytic Leukemia

Business Wire (Wed, 6:30PM)
Jim Cramer's 5 Investing Sweet Spots

at CNBC.com (May 14, 2013)
Midday Movers: GILD, BSX, AES & More

at CNBC.com (May 13, 2013)
Movers & Shakers: Friday’s movers: Regeneron, LinkedIn

at MarketWatch.com (May 3, 2013)
Final Trade: Your First Move for Monday, May 6

at CNBC.com (May 3, 2013)
Early Movers: AIG, LKND, VZ & More

at CNBC.com (May 3, 2013)
Lightning Round: Akamai, Gilead & More

at CNBC.com (May 2, 2013)
S&P 500 Sets Record High, Closes Shy of 1600; Dow Soars 130, Nasdaq Jumps 1%

at CNBC.com (May 2, 2013)
After-Hours Buzz: AIG, LNKD, GILD & More

at CNBC.com (May 2, 2013)
Gilead Sciences Announces First Quarter 2013 Financial Results

Business Wire (May 2, 2013)
Does a Rally Still Count if Led by Defensive Stocks?

at Fox Business (May 2, 2013)
Stocks to Watch: General Motors, AIG are Thursday’s stocks to watch

at MarketWatch.com (May 2, 2013)
Futures Gain After Jobless Claims, ECB Rate Cut

at CNBC.com (May 2, 2013)
Gilead Reports Interim Data From Phase 2 LONESTAR Study

Business Wire (May 2, 2013)
Top Undervalued Pharma Stock: Analyst

at CNBC.com (Apr 29, 2013)
Gilead Receives Complete Response Letters from U.S. Food and Drug Administration for Elvitegravir and Cobicistat

Business Wire (Apr 29, 2013)

GILD vs. ETF Alternatives

Company Description

Gilead Sciences, Inc. (Gilead, we, us or our), incorporated in Delaware on June 22, 1987, is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need. Our mission is to advance the care of patients suffering from life... More

Sector: Healthcare

Industry: Biotechnology

Country: United States

All
| Earnings
| Dividends
| M&A
| On the move

Tuesday, May 21, 5:00 PM Gilead Sciences (GILD) says its Marketing Authorization Application for sofosbuvir, for the treatment of chronic hepatitis C virus, has been fully validated by the European Medicines Agency and is now under assessment. 2 Comments [Healthcare, Global & FX]
Friday, May 17, 4:23 PM Gilead Sciences (GILD +2.4%) finishes higher today after UBS raised its price target to $67 from $63 and reiterated its Buy rating. Analyst Matthew Roden sees ongoing strength for its HIV franchise, saying the firm conducted a survey of top-volume prescribers to gauge initial receptiveness and expected utilization once available,and results were highly supportive of TAF, its HIV treatment, as a next-gen replacement for Viread. 1 Comment [Healthcare, On the Move]
Thursday, May 16, 1:39 PM Infinity Pharmaceuticals (INFI -20.5%) gets slammed by cautious comments out of JPMorgan today, saying that investors are "growing increasingly skittish" ahead of INFI's pending presentation at June's ASCO cancer conference. The company is expected to release Phase 1 clinical safety and tolerability data for IPI-145, its experimental leukemia drug, and while the investment bank predicts "a good showing," it may not be enough to outshine Gilead (GILD -2.3%), Pharmacyclics (PCYC -2.5%) or Roche (RHHBY.OB -0.6%). 3 Comments [Healthcare, On the Move]
Thursday, May 2, 4:49 PM More on Gilead Sciences (GILD): Q1 misses on all counts, but investors appear to be focused more on the potential of its new HIV drug lines. Net earnings rose 63% Y/Y on increased sales for the newer additions to its HIV drug franchise, including Stribild, an HIV cocktail that was launched in late August. The drug contributed $92.1M to product sales in the latest quarter, while sales for Complera, which was approved last August, rose more than three-fold to $148.2M. Shares +0.5% AH. Comment! [Healthcare, Earnings, On the Move]
Thursday, May 2, 4:16 PM Gilead Sciences (GILD): Q1 EPS of $0.48 misses by $0.02. Revenue of $2.53B (11% Y/Y) misses by $50M. (PR). Comment! [Healthcare, Breaking News, Earnings]
Thursday, May 2, 2:24 PM The results of Gilead Sciences' (GILD +4.9%) Lonestar study are a significant positive data point for its hepatitis C program, says Leerink Swann's Howard Liang. He notes that the availability 8-week data, especially in more difficult to treat patients, could influence choice of agents. It's main competition at this point is AbbVie (ABBV), which currently doesn't have an 8-week treatment arm, so the shortened duration could be a significant advantage. More details should be available on its earnings call later today at 4:30 EST: (Webcast). Comment! [Healthcare, On the Move]
Thursday, May 2, 9:59 AM Gilead Sciences (GILD +5.3%) pops after saying it plans to initiate a Phase III trial to evaluate a combination of sofosbuvir and ledipasvir in patients with hepatitis C. Phase II results suggest "once-daily oral therapy with [the combo] may have the potential to cure most genotype 1 HCV infected patients with a remarkably short treatment duration," says Dr. Eric Lawitz, the study's principal investigator. Some have suggested a combination of sofosbuvir and BMY's daclatasvir is preferable, as both are active in genotype 3 HCV whereas ledipasvir may only be effective against genotype 1. (Related: I, II, III) 5 Comments [Healthcare, On the Move]
Thursday, May 2, 9:10 AM Premarket gainers: REGI +23%. CAAS +18%. YELP +12%. MWW +10%. GNRC +9%. NIHD +7%. BZH +7%. GILD +6%. MGM +5%.
Losers: CIG -13%. VLO -7%. TS -6%. 2 Comments [On the Move]
Thursday, May 2, 12:10 AM Notable earnings after Thursday’s close: ACLS, ACTV, ADNC, AGNC, AIG, ALSK, AREX, ARNA, ATHN, BBG, BCOR, BERY, BRKR, CBI, CNQ, DNB, DOLE, DRIV, EGO, ELON, ELX, FBHS, FLR, FLT, GEOS, GHDX, GILD, GMED, GTY, HAIN, HI, HMA, HTGC, INVN, KOG, KRFT, LNKD, MKH, MTZ, MYL, NBIX, NFG, NILE, NSR, ONNN, OPEN, PKT, PWER, QLGC, SKUL, SPF, SPWR, SWN, TDC, THOR, TPX, TSYS, TTMI, WTW, WWWW, XL, ZAGG Comment! [Earnings]
Wednesday, May 1, 5:35 PM Notable earnings after Thursday’s close: ACLS, ACTV, ADNC, AGNC, AIG, ALSK, AREX, ARNA, ATHN, BBG, BCOR, BERY, BRKR, CBI, CNQ, DNB, DOLE, DRIV, EGO, ELON, ELX, FBHS, FLR, FLT, GEOS, GHDX, GILD, GMED, GTY, HAIN, HI, HMA, HTGC, INVN, KOG, KRFT, LNKD, MKH, MTZ, MYL, NBIX, NFG, NILE, NSR, ONNN, OPEN, PKT, PWER, QLGC, SKUL, SPF, SPWR, SWN, TDC, THOR, TPX, TSYS, TTMI, WTW, WWWW, XL, ZAGG Comment! [Earnings]
Saturday, April 27, 10:53 PM Combining Gilead's (GILD) sofosbuvir and Bristol-Myers Squibb's (BMY) daclatasvir cures 100% of hepatitis C patients in 12 weeks (including those who failed treatment with Vertex's (VRTX) Incivek and Merck's (MRK) Victrelis) and looks to be a better treatment option for those with genotype 3 than a combo of sofosbuvir and another GILD drug ledipasvir. The problem: "GILD very clearly wants to develop in-house," one clinician tells Bloomberg. (See also: ABBV's HCV treatment successful; VRTX teams with BMY on HCV trial) 5 Comments [Healthcare]
Tuesday, April 23, 12:43 PM Bristol-Myers Squibb's (BMY +1.3%) oral three-drug combo for hepatitis C cured 94% of patients with 12 or 24 weeks of treatment in a Phase II trial. The company now hopes to start Phase III trials by late 2013. Bristol's positive results add to those of AbbVie (ABBV +2.9%), although Gilead (GILD -0.7%) appears to be ahead in the race to market with an oral hepatitis C drug, having already filed an FDA NDA for its sofosbuvir treatment. (PR) Comment! [Healthcare]
Tuesday, April 23, 7:41 AM AbbVie's (ABBV) five-drug, all oral treatment for hepatitis C wipes the virus out in 88% of patients after eight weeks the company says. Previous results showed the combination treatment rendered the virus undetectable in 99% of those receiving the treatment after 12 weeks. It's a race to market between Abbvie and Gilead Sciences (GILD) for an all oral treatment option capable of supplanting intravenous interferon without affecting cure rates or times. 3 Comments [Healthcare]
Monday, April 22, 3:33 PM Maxim gives a bullish call on Gilead Sciences (GILD +1.8%) today, doubling is price target to $97 from $48. The firm says that recent estimates from private surveys put the Hepatitis C market in Japan much higher than previously thought, perhaps as high as 2M infections. Separately, Morgan Stanley also upped its target on higher HCV estimates as well, but to a much more modest $65 from $46. 5 Comments [Healthcare, On the Move]
Tuesday, April 16, 12:51 PM Gilead Sciences (GILD +2%) gets a lift today after Deutsche Bank reiterates a Buy on the shares and ups its price target from $48 to $69. Deutsche says its built out a monthly HCV market model that includes its new HIV drug TAF as well as Sofosbuvir. The firm projects that Sofosbuvir alone can bring in up to $3.7B in 2014, $8.4B in 2015, and $12.4B at its peak, respectively. Just last week GILD submitted a New Drug Application for Sofsbuvir, saying the drug will shorten treatment time for HCV infection and "reduce or eliminate" the need for injectable treatments. Comment! [Healthcare, On the Move]
Monday, April 8, 5:00 PM Gilead Sciences (GILD) submits FDA New Drug Application for oral sofosbuvir, a hepatitis C treatment. The drug would shorten treatment time for chronic HCV infection to 12-16 weeks from 24-48 weeks and would also "reduce or eliminate" the need for injectable treatments. GILD says data from four Phase 3 studies supports its application. Comment! [Healthcare]

Chines33
Top longs from this price $BP $HIG $GILD $DD $FDX $SODA $EOG $WFM $ADT $YUM $SWK $WY $LEN $LNKD $NFLX $HD $EBAY $PFE $KMP $IGT
May 13, 11:09 PM
Reply (7)

• !Report Abuse
View all 7 replies
Chines33: Yes typically. It all depends on situation. Price, company, news, overall market. Lot of variables.
May 14, 12:07 PM
• !Report Abuse
wheelz23: i was swing trading, but have been day trading...it seems like swing trading is less work, more money for the stocks i was trading...thanks
May 14, 12:46 PM
• !Report Abuse
Add a reply...

140 characters

Chines33
Top medium term short/long pairs $AGNC/$NLY-$IBM/$EMC-$AGN/$GILD-$MCD/$YUM-$ULTA/$WFM-$LINE/$KMP $MMM/$DD $GM/$JCI $SBUX/$SODA
May 13, 10:52 PM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Chines33
Big gainer in $HOLX today. Scratch in $UVXY. Small loss in $APC tight stop attempt and small gain in $GILD scalps.
May 7, 4:15 PM
Reply (4)

• !Report Abuse
View all 4 replies
Chines33: $UXVY was actually an ok gain rather that scratch entered 5.75 out between 5.84-5.89
May 7, 4:29 PM
• !Report Abuse
Chines33: $UVXY ***
May 7, 4:31 PM
• !Report Abuse
Add a reply...

140 characters

ltfinger
New Upgrades (5/3/13): $AIT, $ALK, $AMAG, $AMTD, $AREX, $BDX, $BHI, $CSU, $EMR, $ERX, $ET, $EXLP, $EZA, $FCX, $FIX, $FLR, $FSYS, $GILD
May 6, 9:26 AM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

sprasad03
$GILD - wow taking some profits off the table
May 3, 9:34 AM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

ltfinger
Potential Upgrades (5/2/13): $AIT, $AREX, $BCR, $BDX, $CCG, $CEB, $FIX, $GILD, $IHS, $IMAX, $INFY, $KOLD, $POL, $SRPT, $TDC
May 3, 8:57 AM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

WhisperNumber
$GILD earnings preview http://seekingalpha.com/a/t45d
May 2, 2:15 PM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

sprasad03
$GILD on the rise :-), big gains today even more after results today
May 2, 2:13 PM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

The Wall Street Transcript
Achillion Pharmaceuticals ($ACHN) Remains Undervalued Relative to Gilead ($GILD)- http://su.pr/2KWM0O
May 1, 11:43 AM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

ltfinger
New Downgrades (4/30/13): $AMED, $GILD, $KMP
May 1, 10:20 AM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

LATEST REPLIES

Chines33
Top longs from this price $BP $HIG $GILD $DD $FDX $SODA $EOG $WFM $ADT $YUM $SWK $WY $LEN $LNKD $NFLX $HD $EBAY $PFE $KMP $IGT
May 13, 11:09 PM
Reply (7)

• !Report Abuse
View all 7 replies
Chines33: Yes typically. It all depends on situation. Price, company, news, overall market. Lot of variables.
May 14, 12:07 PM
• !Report Abuse
wheelz23: i was swing trading, but have been day trading...it seems like swing trading is less work, more money for the stocks i was trading...thanks
May 14, 12:46 PM
• !Report Abuse
Add a reply...

140 characters

Chines33
Big gainer in $HOLX today. Scratch in $UVXY. Small loss in $APC tight stop attempt and small gain in $GILD scalps.
May 7, 4:15 PM
Reply (4)

• !Report Abuse
View all 4 replies
Chines33: $UXVY was actually an ok gain rather that scratch entered 5.75 out between 5.84-5.89
May 7, 4:29 PM
• !Report Abuse
Chines33: $UVXY ***
May 7, 4:31 PM
• !Report Abuse
Add a reply...

140 characters

alecman
$GILD HCV cures 1/4/5/6 Geno. Non of the competition can address all.Type one is the hardest to cure 57% population.
Apr 24, 2:35 PM
Reply (2)

• !Report Abuse
View all 2 replies
sprasad03: I have been buying on the dips, not sure why its going down
Apr 24, 3:30 PM
• !Report Abuse
alecman: Lilly's earning lead to BIO sales. Earning is due on Thursday, May 2, 2013. I think they are going beat +.02 cents.
Apr 25, 3:49 AM
• !Report Abuse
Add a reply...

140 characters

Chines33
Will be watching tomorrows earnings for $NFLX $CAT $HAS $HAL $TXN $GILD
Apr 21, 2:23 PM
Reply (1)

• !Report Abuse
View all 1 replies
joeg1969: Loving $GILD $HAS
Apr 22, 1:18 AM
• !Report Abuse
Add a reply...

140 characters

emburns
Nice flash crash in GILD
9/21/12
Reply (1)

• !Report Abuse
View all 1 replies
Bob de'Long: Maybe they will merge with Eli Lilly and then we'll have a GLD LLY.
9/21/12
• !Report Abuse
Add a reply...

140 characters

freefdawatchlist
http://t.co/J5W5mLXX Earning after hour $AMZN $CHH $CSTR $DECK $ DLA $EXPE $GILD $ITMN $MBLX $LEAP $KERX $MET $SWKS $SBUX $TNAV $VRSN $ZNGA
4/26/12
Reply (3)

• !Report Abuse
View all 3 replies
Winning Will: I do not believe KERX is reporting earnings AH.. Where did you get this info
4/26/12
• !Report Abuse
freefdawatchlist: I use http://bit.ly/I8MGxZ It shows KERX earning after hours 5. pm EST
4/26/12
• !Report Abuse
Add a reply...

140 characters

freefdawatchlist
Check out upcoming Fda approval Dates http://bit.ly/H6kqQR $ARNA, $RGEN, $XNPT, $SLXP, $GILD, $ALXA, $PLX,$VVUS, $AMGN,$FURX,$CTIC,$VRTX
4/1/12
Reply (3)

• !Report Abuse
View all 3 replies
freefdawatchlist: don't buy more, because if fda delay it by 3 month, the stock may drop. Check out other stock which haven't rallied up till now.
4/1/12
• !Report Abuse
phemale60: VVUS's Avanafil up for FDA approval late April also. Any info about it? I appreciate your insight!
4/1/12
• !Report Abuse
Add a reply...

140 characters

WheresTheDough
I'd buy $GILD at $43 but doesn't look like that's gonna happen
2/17/12
Reply (2)

• !Report Abuse
View all 2 replies
Chris Lau: It'll get there. give it a few days
2/17/12
• !Report Abuse
WheresTheDough: I hope so. Seems that's where it should be looking at its chart IMHO
2/17/12
• !Report Abuse
Add a reply...

140 characters

Dividend Sheet
Best Healthcare Stock Picks For 2012: http://bit.ly/w32xHl + $MRK $NVS $STJ $TEVA $TMO $CELG $GILD
12/24/11
Reply (2)

• !Report Abuse
View all 2 replies
Ocean Man: I agree w/ NVS and STJ. I'd add SNY.
12/25/11
• !Report Abuse
mitrado: $MRK over 37.5 is quite a suicidal choice... it can go up to 50, but it can as easily fall back to 30... :-/
1/19/12
• !Report Abuse
Add a reply...

140 characters

Marc Chaikin
$GILD Buy any pullbacks Chaikin Power Gauge remains bullish
11/23/11
Reply (3)

• !Report Abuse
View all 3 replies
avickrey: I like GILD, but it is off my radar for a few years after the VRUS purchase.
11/23/11
• !Report Abuse
Marc Chaikin: I have no positions..buying weakness is the best way to get into stocks with bullish potential in a sideways market
11/30/11
• !Report Abuse
Add a reply...

140 characters

Chines33
Looking to add some Pharma tomorrow on a down move..Long PG PRU APA DD EMC SBUX...ABT SNY CELG GILD NVO on watch.
11/29/11
Reply (1)

• !Report Abuse
View all 1 replies
Chines33: I have just covered my silver short in AGQ for a .50 gain.
11/29/11
• !Report Abuse
Add a reply...

140 characters

GILD Gilead Sciences, Inc.

GILD

Gilead Sciences, Inc.